TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Relative Change in Liver Fat Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subjects Who Qualify As Treatment Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Completed Four ACP Activities
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Quality of ECG strips for visual diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Functional Outcomes of Sleep Questionnaire (FOSQ-10)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Major bleedings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Symptomatic recurrent venous thromboembolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Adverse events occurring before the end of the trial
Endpoint domain: Adverse events/effects
Primary endpoint: Biological safety (haematological and biochemical indices)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in patient health questionnaire depression assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in severity of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline average diurnal IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Cochlear Microphonic Potential phase shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Arthritis Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-Year Overall Survival
Endpoint domain: Mortality/survival
Primary endpoint: 4-year Event Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in the International Consultation on Incontinence Questionnaire Overactive Bladder Module (ICIQ-OAB)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the International Consultation on Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life Module (ICIQ-LUTSqol)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in the Patient Perception of Bladder Condition (PPBC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of ultrasound signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diagnostic performance of Dispersion slope for intralobular inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau of Bictegravir (BIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Score of 5 or 6 on the Modified Rankin Scale (mRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Treatment Adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in parenting skill and competence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: overall survival (OS) time
Endpoint domain: Mortality/survival
Primary endpoint: Change in mLUSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of EPA and n-3 PUFA in plasma and erythrocyte lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak (maximum) plasma concentration (Cmax) for total [14C]-radioactivity, [14C]-CC-122, and [14C]-metabolite(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) for total [14C]-radioactivity, [14C]-CC-122, and [14C]-metabolite(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal elimination half-life (t1/2) for total [14C]-radioactivity, [14C]-CC-122, and [14C]-metabolite(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Epileptiform Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of successful xenografts established
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of evidence-based COPD order set
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient completion of colorectal cancer screening
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Increased activation of anterior insula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety profile based on reported adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of 3D power Doppler ultrasound in diagnosing postmenopausal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Revised Fibromyalgia Impact Questionnaire (FIQ-R) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Occurrence of uveitic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Surgical Wound Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Central Nervous System Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurosurgical Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: time until the first severe asthma exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: number of poorly controlled asthma days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients who achieve measured LDL levels <2.6 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients who achieve measured triglycerides <1.5 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Participant satisfaction with intervention structure, timing and content
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants who withdraw from study after enrollment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change From Baseline in Retinal Nerve Fiber Layer (RNFL) Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: adverse events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Equivalence of results of both devices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of T2* MRI scan compared to lumbar puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unilateral vertical jump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Major cardiovascular and Cerebrovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Graft Loss or Death Within 12 Months Post Kidney Transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Wound Infection Rates
Endpoint domain: Adverse events/effects
Primary endpoint: Days required for wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of dysphagia ≥ grade 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean (max, tmax, AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Surface area of a Chronic Pelvic Pressure Ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Frequency, duration and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mode of delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impairment by OCD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety ratings during exposures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically relevant pain increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of Circulating Androgens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Detection of pimonidazole-HCl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Plasma inflammatory-markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative resource utilization in dollars
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to definitive therapy (AAD and or Ablation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Hospital/clinic visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Maximum tolerated dose of topotecan hydrochloride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Reporting Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Satisfaction/preference with the method of treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dopamine receptor density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-reported pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cognitive change postoperatively
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in constipation severity after 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in constipation related quality of life after 8 weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cognitive efficacy as measured by DIAN-MCE
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 90-day postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: reduction in hemoptysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Reflexive functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline Perspective Taking
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline Quality of relationships with YRC
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Serum levels of TGF-β1 and PDGF-BB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal muscle function (muscle quality and muscle power)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall physical function (SPPB score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants Experiencing Any Grade 2 or Higher Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Repeatability of CNVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of CNVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement of CNVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NOTECHS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Patients Achieving Desired Serum Digoxin Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of solicited adverse events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of unsolicited AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Self reported stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Salivary alpha amylase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cost during study participation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Brain Glutamate Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adverse events related to SGB
Endpoint domain: Adverse events/effects
Primary endpoint: All Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Arterial blood gas analysis: partial pressure of oxygen (PO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial blood gas analysis: partial pressure of carbon dioxide (PCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial blood gas analysis: Hemoglobin (Hg) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in plasma Lp(a) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Joint health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean change from baseline in TFBUT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in days from first low-risk score to discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in OCD symptoms in patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in family accommodation in family members
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Number of Drinks Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Peak Drinks on One Occasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Negative Alcohol-related Consequences
Endpoint domain: Adverse events/effects
Primary endpoint: Vigorous Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fruit and Vegetable Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Durability of Response (ACR20 Response or Greater)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Durability of Response (PASI-50 Response or Greater)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score from Cardiff Test for retention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Framingham heart risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ileal amino acid digestibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Asthma-related health-care utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in serum LDL-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Spleen Volume Reduction Response (≥ 35%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Spleen Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Symptom Score Analysis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decline in total IgE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in response to Patient Health Questionnaire 9
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in perception and satisfaction of received information
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Skin Irritation Scores at 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin Irritation Scores at 48 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin Irritation Scores at 72 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of days until disappearance of hypopyon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular complications from the infection
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean HI Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects Who Reached Seroprotection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in the Seroconversion Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Extremity pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effort-based Decision-making (EBDM) Task Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Preptin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum Amylin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Correct classification of cases of PD and controls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of selective cerebral hypothermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of selective cerebral hypothermia
Endpoint domain: Adverse events/effects
Primary endpoint: Patient survival post transplantation at Day 30
Endpoint domain: Mortality/survival
Primary endpoint: Primary Graft Dysfunction (PGD) Grade 3 in the first 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in orofacial pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of pro-inflammatory macrophages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical Benefit Rate (CR+PR+SD≥6months)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of the Test device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeatability of the Test device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feelings of doctors caring for colleagues
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Gastrointestinal microbiota examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Examination of IL-8 in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Examination of urine IFABP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Calprotectin examination in stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Alpha 1 antitrypsin examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: Blood levels of study drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of participants with operational tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients reaching target blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients reaching LDL-C targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[infinity])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of stay in the neonatal intensive care unit (NICU)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of dosages taken within 2 hours of prescribed time
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pharmacy pill count
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Subjects With Tumor Uptake of 111^In-CS-1008 in Target Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Tumor Uptake of 111^In-CS-1008
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean 111^In-CS-1008 Serum Half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Defecatory disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Chest Compression Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes